Gilead's CVS exclusive may best AbbVie's Express Scripts hepatitis C deal
This article was originally published in Scrip
Executive Summary
Gilead Sciences inked an exclusive agreement with CVS/Caremark under which the pharmacy benefit manager (PBM) will pay only for Gilead's drugs to treat the hepatitis C virus (HCV) in a deal that could be even better than AbbVie's recent arrangement with the PBM Express Scripts.